Beginning of the development of RetinAI Discovery®, a first in-class data management platform integrated with AI modules

Start of large projects involving RetinAI Discoveryfor Research and Clinical Study support in EU

RetinAI Discovery is CE marked and a master collaboration agreement is signed with Novartis for Discovery Unity & Discovery for Clinical Trials

FDA clearance for RetinAI Discovery and expansion to new disease areas: diabetic retinopathy, diabetic macular edema, glaucoma, geographic atrophy

CE Marking Certificate for Discovery as a Class IIa Medical Device under the Medical Devices Regulation ((EU)2017/745)

4 new upgrades

Certification of our 4 of our devices under the Medical Devices Regulation ((EU)2017/745): our platform RetinAI Discovery and 3 of our AI models (Macula Biomarkers, Layer Segmentation & Fluid Segmentation)